Compare · MDLN vs PROF
MDLN vs PROF
Side-by-side comparison of Medline Inc. (MDLN) and Profound Medical Corp. (PROF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PROF operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $50.91B, about 193.0x PROF ($263.8M).
- Over the past year, MDLN is down 4.8% and PROF is up 26.7% - PROF leads by 31.5 points.
- PROF has been more active in the news (6 items in the past 4 weeks vs 4 for MDLN).
- MDLN has more recent analyst coverage (25 ratings vs 7 for PROF).
- Company
- Medline Inc.
- Profound Medical Corp.
- Price
- $38.78+3.02%
- $7.27+5.67%
- Market cap
- $50.91B
- $263.8M
- 1M return
- +7.57%
- +10.49%
- 1Y return
- -4.83%
- +26.66%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 4
- 6
- Recent ratings
- 25
- 7
Profound Medical Corp.
Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Latest MDLN
- Medline strengthens California distribution network with new 1 million-square-foot facility in Perris
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
Latest PROF
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
- SEC Form EFFECT filed by Profound Medical Corp.
- Profound Medical Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits